EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms

Xin Li, Yi Li, Yuancheng Chen iD, Shuangchen Cong, Beining Guo, Xiaofen Liu, Zhiwei Huang, Jing Zhang iD

Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)

DOI: 10.1093/jac/dkag214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.06.2026. Verfasst von Xin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Cefoperazone, Sulbactam, Anti-Bacterial Agents, Neutropenia. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Shanghai Talent Awards, Shanghai Science and Technology Innovation Action Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Cefoperazone-sulbactam, a β-lactam/β-lactamase inhibitor combination, is widely used against ESBL-producing Gram-negative pathogens. This study investigated the in vivo pharmacokinetics/pharmacodynamics (PK/PD) of 1:1 and 2:1 cefoperazone-sulbactam formulations in neutropenic murine thigh and lung infection models.

Methods

Eleven ESBL-producing Gram-negative isolates with varying MICs were used to establish murine thigh and lung infection models. The plasma and epithelial lining fluid (ELF) pharmacokinetics of cefoperazone and sulbactam were evaluated over a wide dose range. Five dose-fractionation experiments were conducted to identify the PK/PD index most correlated with efficacy, and dose–escalation to determine PK/PD targets.

Results

All isolates exhibited cefoperazone MICs ≥ 64 mg/L, reduced by 8- to 16-fold by sulbactam at a 1:1 or 2:1 ratio. Cefoperazone and sulbactam showed linear pharmacokinetics across the dose range, well described by a two-compartmental model. Plasma protein binding was 57% for cefoperazone and 3% for sulbactam. ELF penetration was 0.12 for cefoperazone and 0.21 for sulbactam, which were used to determine the ELF-based targets. PK/PD targets reflecting the primary active component against each pathogen were reported. Cefoperazone %fT > MIC was used as the PK/PD index for E. coli and K. pneumoniae, the magnitude for 1-log10 cfu bacterial reduction was 50.3% (1:1) and 51.3% (2:1) in the thigh infection model, 52.4% (1:1) and 75.6% (2:1) in the lung infection model. For A. baumannii, sulbactam was identified as the primary active component, and the 1-log10 cfu %fT > MIC target for sulbactam was 68.7%.

Conclusions

Cefoperazone-sulbactam demonstrated strong in vivo antibacterial activity against the 11 tested isolates. This study established PK/PD targets under varied conditions, providing a valuable foundation for optimizing the clinical application of cefoperazone-sulbactam.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefoperazoneSulbactamAnti-Bacterial AgentsNeutropeniaGram-Negative BacteriaGram-Negative Bacterial InfectionsAnimalsMicrobial Sensitivity TestsThighMiceDisease Models, AnimalFemaleThird Generation CephalosporinsLung

Substanzen

CefoperazoneSulbactamAnti-Bacterial AgentsThird Generation Cephalosporins

Autor:innen und Institutionen

  • Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Professional Technical Service Platform for Comprehensive Preclinical Pharmacodynamic Evaluation and Clinical Translation of Antibacterial Agents, Huashan Hospital, Fudan University, Shanghai200040, China.
  • Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • PfizerPharmaceutical Ltd., Clinical Pharmacology, Development China, Beijing 100027, China.

ORCID-Profile: Yuancheng Chen, Jing Zhang

Förderung

  • Shanghai Talent Awards
  • Shanghai Science and Technology Innovation Action Plan

Zitieren

APA

Li, X., Li, Y., Chen, Y., Cong, S., Guo, B., Liu, X., Huang, Z., & Zhang, J. (2026). Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag214

Vancouver

Li X, Li Y, Chen Y, Cong S, Guo B, Liu X, et al. Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag214

BibTeX
@article{Li2026,
  author = {Li, Xin and Li, Yi and Chen, Yuancheng and Cong, Shuangchen and Guo, Beining and Liu, Xiaofen and Huang, Zhiwei and Zhang, Jing},
  title = {Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {7},
  doi = {10.1093/jac/dkag214}
}
Kostenlos starten →